CORRECTION

Open Access



Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti^{1,2*}, Gabriella Egeo¹, Cinzia Aurilia¹, Florindo d'Onofrio³, Maria Albanese^{4,5}, Ilaria Cetta⁶, Paola Di Fiore⁷, Maurizio Zucco⁸, Massimo Filippi⁹, Francesco Bono¹⁰, Claudia Altamura¹¹, Stefania Proietti¹², Stefano Bonassi^{12,13}, Fabrizio Vernieri¹⁴ and for the FRIEND-Study Group

Correction to: J Headache Pain 22, 46 (2022) https://doi.org/10.1186/s10194-022-01396-x

Following the publication of the original article [1], we were notified that the name of the 9th author was incorrectly spelled as Massimo FilippiBonassi, instead of Massimo Filippi.

The original article has been corrected.

Author details

¹Headache and Pain Unit, IRCCS San Rafaele Pisana, Rome, Italy. ²San Rafaele University, Rome, Italy. ³Neurology Unit, San Giuseppe Moscati Hospital, Avellino, Italy. ⁴Regional Referral Headache CenterNeurology Unit, University Hospital Tor Vergata, Rome, Italy. ⁵Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.⁶Headache Unit, Department of Neurology, Scientifc Institute San Rafaele Hospital, Vita-Salute University, Via Olgettina, 48, Milan, Italy. ⁷Headache Center, ASST Santi Paolo Carlo, Milan, Italy. ⁸Headache Center, Neurlogy Unit, San Camillo-Forlanini Hospital, Rome, Italy. 9Neurology Unit, IRCCS San Rafaele Scientifc Institute, Vita-Salute San Raffaele University, Milan, Italy. ¹⁰Center for Headache and Intracranial Pressure Disorders, Neurology Unit, A.O.U. Mater Domini, Catanzaro, Italy.¹¹Headache and Neurosonology Unit, Policlinico Universitario Campus Bio-Medico, Rome, Italy. ¹²Clinical and Molecular Epidemiology, IRCCS San Rafaele, Roma, Italy.¹³Department of Human Sciences and Quality of Life Promotion, San Rafaele University, Rome, Italy.¹⁴Headache and Neurosonology Unit, Campus BioMedico University Hospital, Rome, Italy.

The original article can be found online at https://doi.org/10.1186/s10194-022-01396-x.

*Correspondence: piero.barbanti@sanrafaele.it ² San Rafaele University, Rome, Italy Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published online: 28 April 2022

Reference

 Barbanti P et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 22:46. https://doi.org/ 10.1186/s10194-022-01396-x